Cutting-edge genomic studies from the Wellcome Sanger Institute, University of Cambridge, and Cambridge University Hospitals reveal distinct mutational signatures caused by various chemotherapy drugs in healthy blood cells. Using whole genome sequencing, researchers have characterized specific DNA damage associated with common chemotherapy agents, including differential effects among platinum-based drugs. This work advances understanding of chemotherapy’s long-term impacts, informing safer cancer treatment protocols and personalized therapeutic choices.